financetom
Business
financetom
/
Business
/
Trump says he will continue to make deals like Intel one
News World Market Environment Technology Personal Finance Politics Retail Business Economy Cryptocurrency Forex Stocks Market Commodities
Trump says he will continue to make deals like Intel one
Aug 25, 2025 7:25 AM

WASHINGTON (Reuters) -U.S. President Donald Trump on Monday said he would make deals with other companies similar to the one he announced last week with Intel.

Trump on Friday said the U.S. would take a 10% stake in Intel under a deal with the struggling chipmaker that converts government grants into an equity share.

 "I will make deals like that for our Country all day long," Trump said in a post on Truth Social.

 "I love seeing their stock price go up, making the USA RICHER, AND RICHER. More jobs for America!" he added.

Trump also said in the post that he would help companies that make similar "lucrative" deals with U.S. states, but didn't provide details.

The Intel deal will ensure that the chipmaker will receive about $10 billion in funds for building or expanding factories in the U.S.

Under the agreement, the U.S. will purchase a 9.9% stake in Intel for $8.9 billion, or $20.47 per share, which represents a discount of about $4 from Intel's closing share price of $24.80 on Friday.

The purchase of the 433.3 million Intel shares will be made with funding from the $5.7 billion in unpaid grants from the Biden-era CHIPS Act and $3.2 billion awarded to Intel for the Secure Enclave program, also awarded under Trump's predecessor, Democratic President Joe Biden.

Comments
Welcome to financetom comments! Please keep conversations courteous and on-topic. To fosterproductive and respectful conversations, you may see comments from our Community Managers.
Sign up to post
Sort by
Show More Comments
Related Articles >
AbbVie, Xilio Collaborate on Tumor-Activated Immunotherapies
AbbVie, Xilio Collaborate on Tumor-Activated Immunotherapies
Feb 12, 2025
08:18 AM EST, 02/12/2025 (MT Newswires) -- AbbVie ( ABBV ) and Xilio Therapeutics (XLO) said Wednesday they are collaborating and have signed an option-to-license agreement to develop tumor-activated, antibody-based immunotherapies, including masked T-cell engagers. The companies said they will combine Xilio's tumor-activation technology with AbbVie's ( ABBV ) research and development efforts in oncology. As part of the deal,...
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise
AnaptysBio's Rheumatorid Arthritis Drug Meets Primary Endpoint in Phase 2 Trial; Shares Rise
Feb 12, 2025
08:20 AM EST, 02/12/2025 (MT Newswires) -- AnaptysBio ( ANAB ) said Wednesday that a phase 2b trial of its investigational drug rosnilimab to treat moderate-to-severe rheumatoid arthritis achieved its primary and secondary endpoints. Patients in the study received either 100 milligram or 400 milligram doses of rosnilimab every four weeks, 600 milligrams every two weeks, or placebo, the company...
Kroger names PepsiCo executive David Kennerley as CFO
Kroger names PepsiCo executive David Kennerley as CFO
Feb 12, 2025
Feb 12 (Reuters) - Kroger ( KR ) said on Wednesday PepsiCo executive David Kennerley would succeed Todd Foley as the company's chief financial officer, effective April 3. Foley had taken over the role on an interim basis when former CFO Gary Millerchip stepped down last February. Kroger ( KR ) in December ended a two-year effort to merge with...
Lazard Posts Increase in Assets Under Management for January
Lazard Posts Increase in Assets Under Management for January
Feb 12, 2025
08:19 AM EST, 02/12/2025 (MT Newswires) -- Lazard ( LAZ ) reported preliminary assets under management Wednesday of $233.02 billion as of Jan. 31, up from $226.33 billion a month earlier. The asset management firm reported a market appreciation of $6.1 billion, foreign exchange appreciation of $400 million, and net inflows of $300 million for January. ...
Copyright 2023-2026 - www.financetom.com All Rights Reserved